Our Technology

The Microbiome

The microbiome – all the microbes that reside in and on the human body – is a new, exciting, and fast-developing field, offering abundant opportunities for the development of new medicines. The composition of bacteria forming the microbiome, mainly gut bacteria, has been linked to various health conditions, including allergies, gastrointestinal disorders, obesity, and cancer. In some diseases we can pinpoint a specific, pathogenic bacteria in the microbiome, which may induce or worsen the condition. Following target validation, BiomX is developing phage therapies to target and destroy these specific bacteria and restore the microbiome to a healthy state.

Phage Therapies

To develop a phage therapy, we hunt for the best suited phage, use advanced synthetic biology to engineer these phage if needed, and optimize the phage cocktail in vitro and in-vivo for best activity.

Target Bacteria Discovery Validation

We access target bacteria either through utilizing our proprietary computational platform or through licensing in from academia or industry. Candidate targets then undergo a robust process of target validation that includes analysis of patient cohorts as well as in-vitro, ex-vivo and animal validation models. Our patient cohort analysis entails microbiome sample collection globally, from both patients and healthy people. We then evaluate multiple parameters, including prevalence and abundance of these targets in

sick vs. healthy people and correlation to clinical phenotypes such as a link between target bacteria abundance and flares in IBD patients. Our end goal is to advance valid targets to phage discovery, where we seek a phage cocktail that target and destroy bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases.

Target Bacteria Discovery Validation

We access target bacteria either through utilizing our proprietary computational platform or through licensing in from academia or industry. Candidate targets then undergo a robust process of target validation that includes analysis of patient cohorts as well as in-vitro, ex-vivo and animal validation models. Our patient cohort analysis entails microbiome sample collection globally, from both patients and healthy people. We then evaluate multiple parameters, including prevalence and abundance of these targets in sick vs. healthy people and correlation to clinical phenotypes such as a link between target bacteria abundance and flares in IBD patients. Our end goal is to advance valid targets to phage discovery, where we seek a phage cocktail that target and destroy bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases..

Biomarker Discovery

Our discovery platform for predictive microbiome-based biomarkers
The microbiome has shown promise as a predictive tool for the existence and stage of disease in IBD, liver disease, colorectal cancer and cardiovascular disease, among others. In recent studies it has also demonstrated the potential to predict response to specific therapeutics in IBD and immuno-oncology. Our first-of-its-kind XMarker platform uses a unique metagenomics-based approach to discover predictive microbial genomic signatures to be further developed into biomarkers. The platform combines ultra-high-resolution DNA analysis, AI techniques and high-scale cloud computing resources to build classifiers of high sensitivity and specificity.

OUR INVESTORS